Search filters

List of works by Begoña Martin-Castillo

Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile

scientific article

Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells

scientific article published on March 2012

An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients

scientific article

Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties

scientific article published on 13 May 2015

Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype

scientific article

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment ⬇️

scientific article published on December 1, 2012

BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.

scientific article

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells

scientific article

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas

scientific article published on 12 October 2015

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib

scientific article

Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer

scientific article published on 7 October 2016

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer

scientific article published on March 2015

Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast ⬇️

scientific article published on October 27, 2010

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin

scientific article published on September 2013

Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics

scientific article

Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).

scientific article

EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells

scientific article published on 30 May 2017

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).

scientific article published on 19 September 2012

Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells

scientific article published on 16 December 2010

Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells

scientific article published on 14 February 2018

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations

scientific article published on January 2013

If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials

scientific article published on 26 October 2009

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-li

scientific article

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

scientific article published on January 2011

Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs ⬇️

scientific article published on July 1, 2012

Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity

scientific article published on 15 October 2017

Metformin and cancer: Quo vadis et cui bono?

scientific article published on 23 June 2016

Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena

scientific article published on 15 March 2010

Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer ⬇️

scientific article published on November 1, 2011

Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab

scientific article

Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency

scientific article

Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205.

scientific article published on 15 March 2012

Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status

scientific article published on September 25, 2010

Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation

scientific article

Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts ⬇️

scientific article published on April 1, 2012

Metformin: Multi-faceted protection against cancer ⬇️

scientific article published on December 1, 2011

Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a ⬇️

scientific article published on April 1, 2011

Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions

scientific article published on 19 May 2011

Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells

scientific article published on August 2013

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo

scientific article published on January 2013

Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells

scientific article published on January 2011

Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin

scientific article published on 17 September 2013

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer

scientific article published on 12 September 2016

The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells

scientific article published on 2 April 2013

The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells

scientific article

The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells

scientific article published on January 1, 2011

The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer

scientific article published on January 2013

Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.

scientific article

Paulina is supported by:

About Paulina

Help